Last update 01 Nov 2024
Cogentis Therapeutics, Inc.

Cogentis Therapeutics, Inc.

Startups
|
Private Company|
2015|
Maryland, United States
|
< 10
|
www.cogentistherapeutics.com

Overview

Tags

Nervous System Diseases
Endocrinology and Metabolic Disease
Other Diseases
Synthetic peptide

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease1
Nervous System Diseases1
Top 5 Drug TypeCount
Synthetic peptide1
Top 5 TargetCount
CDK(Cyclin-dependent kinase)1

Related

2
Drugs associated with Cogentis Therapeutics, Inc.
CT-526
Target
CDK
Mechanism
CDK inhibitors
Active Org.
Cogentis Therapeutics, Inc.Cogentis Therapeutics, Inc.Startup
Originator Org.
Cogentis Therapeutics, Inc.Cogentis Therapeutics, Inc.Startup
Active Indication
Alzheimer Disease [+1]
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
CT-814
Target-
Mechanism-
Active Org.-
Originator Org.
Cogentis Therapeutics, Inc.Cogentis Therapeutics, Inc.Startup
Active Indication-
Inactive Indication
Frontotemporal Dementia
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Cogentis Therapeutics, Inc.
Login to view more data
0 Patents (Medical) associated with Cogentis Therapeutics, Inc.
Login to view more data
100 Deals associated with Cogentis Therapeutics, Inc.
Login to view more data
100 Translational Medicine associated with Cogentis Therapeutics, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
CT-526
 ( CDK )		Alzheimer Disease
More
Preclinical
CT-814
Frontotemporal Dementia
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free